ProShare Advisors’s Ovid Therapeutics OVID Stock Holding History

ProShare Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.9K	Buy	+20,049	New	+$51.7K	﹤0.01%	1837
2025 Q2	–	Sell	-12,754	Closed	-$3.98K	–	2156
2025 Q1	$3.98K	Sell	12,754 -3,830	-23%	-$2.35K	﹤0.01%	2078
2024 Q4	$15.5K	Buy	16,584 +1,263	+8%	+$1.41K	﹤0.01%	2258
2024 Q3	$18.1K	Buy	15,321 +2,956	+24%	+$3.09K	﹤0.01%	2049
2024 Q2	$9.51K	Sell	12,365 -3,301	-21%	-$9.19K	﹤0.01%	1838
2024 Q1	$47.8K	Buy	15,666 +1,281	+9%	+$4.29K	﹤0.01%	1908
2023 Q4	$46.3K	Buy	+14,385	New	+$49.2K	﹤0.01%	1870
2021 Q4	–	Sell	-14,511	Closed	-$49K	–	2345
2021 Q3	$49K	Buy	14,511 +2,328	+19%	+$8.49K	﹤0.01%	1966
2021 Q2	$48K	Sell	12,183 -9,306	-43%	-$36.7K	﹤0.01%	2361
2021 Q1	$86K	Buy	21,489 +1,156	+6%	+$3.84K	﹤0.01%	2182
2020 Q4	$47K	Buy	+20,333	New	+$94.8K	﹤0.01%	2050

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ProShare Advisors's OVID Position: Q2 2026 in Review

ProShare Advisors opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 20,049 shares worth $53.9K. The stake represents ﹤0.01% of the portfolio and ranks #1837 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in OVID as recently as Q1 2025.

ProShare Advisors first reported a position in OVID in Q4 2020 and has held it in 11 quarters since. The position peaked at $86K in Q1 2021. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

ProShare Advisors held 20,049 shares of Ovid Therapeutics worth $53.9K as of Q2 2026.
Ovid Therapeutics was a new ProShare Advisors position in Q2 2026.
Ovid Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1837 holding.
ProShare Advisors first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 11 quarters since.
ProShare Advisors's Ovid Therapeutics position peaked at $86K in Q1 2021.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.